Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ORG-100006227 | Other Identifier | ESCRS (European society of Cataract and Refractive Surgeons) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Clinical Trials Centre Cologne | OTHER |
| European Society of Cataract and Refractive Surgeons | OTHER |
Not provided
Not provided
Not provided
The purpose of the study is to investigate whether there is a difference in BCVA in patients who receive one of the following two surgeries: intervention group (arm 1) cataract surgery alone and control group (arm 2) cataract surgery combined with removal of the diseased endothelial cells and the attached Descemet's membrane followed by transplantation of a healthy endothelial cell layer with attached Descemet's membrane ("triple-DMEK" group; comparator therapy).
The secondary objectives are to compare the two surgical methods with regard to other visual functions and optical as well as morphological differences, to safety, to quality of life, and to safety.
After signing the informed consent, patients are screened for eligibility for the trial regarding in- and exclusion criteria.
Different tests will be performed like ocular examination including slit lamp examination, fundus examination, IOP measurement, BCVA, Pentacam imaging, and Macular-OCT, vital signs. In addition, women below age of 60 have to perform a urine pregnancy test. Once all inclusion criteria and none of the exclusion criteria are met, the patient will be enrolled into the trial and will receive a subject-ID.
The Baseline Visit can take place up to 7 days after enrolment of the subject into the clinical trial. At the Baseline Visit a photograph of the cornea in retroillumination will be taken (can be taken either at Screening & Enrolment Visit or at Baseline Visit) and uploaded into the eCRF for central grading by CORIC.
In addition, subjects have to complete vision related quality of life questionnaires and changes in relevant medical history/concomitant diseases as well as concomitant medications have to be documented.
Furthermore, a contrast sensitivity test and an optical quality test (if device available) will be peformed.
After all investigations are completed, the subject will be randomised via the central 24-7 Internetrandomisation service ALEA and distributed to the respective treatment groups.
Intervention (surgery):
On that day and before starting intervention all women below 60 years undergo a pregnancy test and changes in relevant medical history/concomitant diseases have to be documented. In arm 1 (intervention group) patients undergo exclusively cataract surgery, in arm 2 (control group) patients undergo triple-DMEK, i.e. cataract surgery and DMEK.
The immediate follow-up appointments for clinical examinations are, as per standard of care, at the discretion of the respective trial centres treating physician.
The Post-operative Visit will take place 22 weeks ± 14 days after the surgical intervention. During the Post-operative Visit an ocular examination including slit lamp examination, fundus examination, IOP measurement, BCVA, Pentacam imaging, contrast sensivity test, an optical quality test (if device available), and Macular-OCT will be performed. In addition, vital signs will be taken and subjects have to complete the vision related quality-of-life questionnaires again. Concomitant medications and AEs/SAEs have to be documented.
The duration of the clinical trial for every individual subject will be up to 29 weeks (time from Screening & Enrolment Visit to Post-operative Visit).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental intervention /arm 1 | Experimental | After randomisation the investigational therapy (arm 1), patients undergo a cataract surgery with preservation of the diseased endothelial cells. The cataract surgery will take approximately 10-20 minutes. The follow-up period after surgery will be 22 weeks ± 14 days. |
|
| Control intervention /arm2 | Other | After randomisation, patients in the comparator therapy (arm 2) undergo triple-DMEK which is a cataract surgery combined with DMEK (removal of the diseased endothelial cells followed by transplantation of a healthy endothelial cell layer). Triple-DMEK takes approximately 5-10 minutes longer than cataract surgery. The follow-up period after surgery will be 22 weeks ± 14 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Intervention group /arm 1 (Cataract surgery alone) | Procedure | Cataract surgery (arm 1) is performed using a small incision technique. The tunnel is used both for cataract surgery and for implantation of the DMEK graft (arm 2). The centres confirmed that the main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. If cataract surgery alone (arm 1) is performed, a thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag. The centers confirmed that Barret Universal II formula is the standard IOL calculation formula for both groups and for all axial lengths. |
| Measure | Description | Time Frame |
|---|---|---|
| BCVA 22 | Best corrected visual acuity (BCVA) is messured with EDTRS-charts (transformed to logMAR) | 22 weeks +/- 14 days after surgery |
| Measure | Description | Time Frame |
|---|---|---|
| Change in visual acuity (BCVA) | Specific measurement variable: ETDRS-charts (transformed to logMAR); Analysis metric (participant level): Difference value at follow-up- baseline value Method of aggregation (summary measure for each study group): Mean difference | Baseline (pre-op) and 22 weeks +/- 14 days after initial surgery |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Björn Bachmann, Prof. | Contact | 0049-221 478-87476 | bjoern.bachmann@uk-koeln.de |
| Name | Affiliation | Role |
|---|---|---|
| Björn Bachmann, Prof. | University Hospital Cologne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Ophthalmology, Aarhus University Hospital | Not yet recruiting | Aarhus N | Central Jutland | DK- 8200 | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The trial will be a prospective, randomised, controlled, European, multicentre, open clinical trial in which patients with FECD and cataract will receive either cataract surgery without DMEK (intervention goup/arm 1) or triple-DMEK (DMEK in combination with cataract surgery; control group/arm 2).
(Protocol V02_0_TC page 37)
Not provided
Not provided
After screening and enrollement subjects will be randomly allocated to the trial groups (cataract surgery versus triple-DMEK, allocation rate 1:1)
Not provided
|
| Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK) | Procedure | After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%. |
|
| Contrast sensitivity |
Specific measurement variable: Total score of Freiburg Vision Test "FrACT"; Analysis metric (participant level): Value Method of aggregation (summary measure for each study group): Mean |
| 22 weeks +/- 14 days after initial surgery |
| Change in contrast sensitivity | Specific measurement variable: Total score of Freiburg Vision Test "FrACT"; Analysis metric (participant level): Difference Value at follow-up-baseline value; Method of aggregation (summary measure for each study group): Mean difference | 22 weeks +/- 14 days after initial surgery |
| Optical quality measured by HD-analyzer | Specific measurement variable: Total score of objective scattering index (OSI); Analysis metric (participant level): Value Method of aggregation (summary measure for each study group): Mean | 22 weeks +/- 14 days after initial surgery |
| Change in optical quality measured by HD-analyzer | Specific measurement variable: Total score of objective scattering index (OSI); Analysis metric (participant level): Difference value at follow-up- baseline value Method of aggregation (summary measure for each study group): Mean difference | 22 weeks +/- 14 days after initial surgery |
| Optical quality measured by HD-analyzer | Specific measurement variable: Total score of Modulation transfer function (MTF) cut-off; Analysis metric (participant level): value Method of aggregation (summary measure for each study group): Mean | 22 weeks +/- 14 days after initial surgery |
| Change in optical quality measured by HD-analyzer | Specific measurement variable: Total score of Modulation transfer function (MTF) cut-off; Analysis metric (participant level): Difference value at follow-up - baseline value Method of aggregation (summary measure for each study group): Mean difference | 22 weeks +/- 14 days after initial surgery |
| Optical quality measured by HD-analyzer | Specific measurement variable: Total score of Strehl ratio; Analysis metric (participant level): Value Method of aggregation (summary measure for each study group): Mean | 22 weeks +/- 14 days after initial surgery |
| Change in Optical quality measured by HD-analyzer | Specific measurement variable: Total score of Strehl ratio; Analysis metric (participant level): Difference value at follow-up- baseline value Method of aggregation (summary measure for each study group): Mean difference | 22 weeks +/- 14 days after initial surgery |
| Refractive accuracy:spherical equivalent | Specific measurement variable: Deviation from target refraction from IOL calculation [D], Analysis metric (participant level): Value Method of aggregation (summary measure for each study group): Mean numerical prediction error (ME) and Mean absolute prediction error (MAE) | 22 weeks +/- 14 days after initial surgery |
| Corneal topography/ tomography parameters | Specific measurement variable: Corneal densitometry (grayscale unit GSU) (anterior, central, posterior and total layer) Analysis metric (participant level): Value; Method of aggregation (summary measure for each study group): Mean | 22 weeks +/- 14 days after initial surgery |
| Change in corneal topography/tomography parameters | Specific measurement variable: Corneal densitometry (grayscale unit GSU) (anterior, central, posterior and total layer); Analysis metric (participant level): Difference value at follow-up - baseline value; Method of aggregation (summary measure for each study group): Mean difference | At baseline and 22 weeks +/- 14 days after initial surgery |
| Central corneal thickness (CCT) | Specific measurement variable: CCT measured by Pentacam [μm]; Analysis metric (participant level): Value; Method of aggregation (summary measure for each study group): Mean | At baseline and 22 weeks +/- 14 days after initial surgery |
| Change in central corneal thickness (CCT) | Specific measurement variable: CCT measured by Pentacam [μm]; Analysis metric (participant level): Difference value at follow-up - baseline value Method of aggregation (summary measure for each study group): Mean difference | At baseline and 22 weeks +/- 14 days after initial surgery |
| Quality of life | Specific measurement variable: Catquest-9SF (all centers) and V-Fuchs (Germany only); Analysis metric (participant level): Total score [no dimension]; Method of aggregation (summary measure for each study group): Mean | 22 weeks +/- 14 days after initial surgery |
| Change in quality of life | Specific measurement variable: Catquest-9SF (all centers) and V-Fuchs (Germany only); Analysis metric (participant level): Difference total score at follow-up- baseline total score; Method of aggregation (summary measure for each study group): Mean difference | At baseline and at 22 weeks +/- 14 days after initial surgery |
| Change in central retinal thickness | Specific measurement variable: Measured by OCT Analysis metric (participant level): Difference value at follow-up- baseline value; Method of aggregation (summary measure for each study group): Mean difference | At baseline and at 22 weeks +/- 14 days after initial surgery |
| Change in intraocular pressure (IOP) | Specific measurement variable: IOP [mmHg] Analysis metric (participant level): Difference value at follow-up - baseline value Method of aggregation (summary measure for each study group): Mean difference | At baseline and at 22 weeks +/- 14 days after initial surgery |
| Additional ocular surgeries | Specific measurement variable: Per patient anamnesis Analysis metric (participant level): Value (yes/no) Method of aggregation (summary measure for each study group): Proportion | At baseline and at 22 weeks +/- 14 days after initial surgery |
| Endothelial decompensation with indication for endothelial keratoplasty (either planned or already performed) | Specific measurement variable: Per patient anamnesis (decision made by treating ophthalmologist; incl. ophthalmologist outside the study team) Analysis metric (participant level): Value [yes/no] Method of aggregation (summary measure for each study group): Proportion | 22 weeks +/- 14 days after initial surgery |
| Cystoid macular edema | Specific measurement variable: CME visualized by OCT Analysis metric (participant level): Value [yes/no] Method of aggregation (summary measure for each study group): Proportion | 22 weeks +/- 14 days after initial surgery |
| Klinik für Ophthalmologie des Universitätsklinikums Köln | Recruiting | Cologne | North Rhine-Westphalia | 50937 | Germany |
|
| Radboud-Universität Nijmegen | Not yet recruiting | Nijmegen | Gelderland | GA 6525 | Netherlands |
|
| Instituto de microcirugía ocular; Departamento de Cornea y Cirugia Refractiva | Not yet recruiting | Barcelona | Barcelona | 08035 | Spain |
|
| ID | Term |
|---|---|
| D002386 | Cataract |
| D005642 | Fuchs' Endothelial Dystrophy |
| ID | Term |
|---|---|
| D007905 | Lens Diseases |
| D005128 | Eye Diseases |
| D003317 | Corneal Dystrophies, Hereditary |
| D003316 | Corneal Diseases |
| D015785 | Eye Diseases, Hereditary |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D002387 | Cataract Extraction |
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D054140 | Refractive Surgical Procedures |
| D013508 | Ophthalmologic Surgical Procedures |
| D013514 | Surgical Procedures, Operative |
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
| D008722 | Methods |
Not provided
Not provided